| Autor: |
Sue Ping, Thang, John, Violet, Shahneen, Sandhu, Amir, Iravani, Tim, Akhurst, Grace, Kong, Aravind, Ravi Kumar, Declan G, Murphy, Scott G, Williams, Rodney J, Hicks, Michael S, Hofman |
| Rok vydání: |
2018 |
| Předmět: |
|
| Zdroj: |
European urology oncology. 2(6) |
| ISSN: |
2588-9311 |
| Popis: |
Prostate-specific membrane antigen (PSMA) is overexpressed in metastatic castration-resistant prostate cancer (mCRPC) and represents a target for imaging and therapy. We undertook a prospective trial ofTo determine outcomes for men screened for the trial but not treated because of low PSMA expression.Patients screened withSubsequent treatments received were recorded. Kaplan-Meier analysis was used to determine overall survival from date of screening.Sixteen patients (24%) had low PSMA expression (n=8) or discordant FDG-avid disease (n=8). The median prostate-specific antigen doubling-time was 2.1mo. Eleven patients had Gleason ≥8 disease. All patients had previously progressed after docetaxel, 44% after cabazitaxel, and 94% after abiraterone and/or enzalutamide. Nine patients had subsequent systemic antitumour treatment. Fifteen patients died, with median OS of 2.5mo (95% confidence interval 1.7-5.0). Study limitations include uncertainty for imaging thresholds that define low PSMA expression. It is also possible that theranostic therapy could have improved survival in this cohort.Low PSMA expression or discordant FDG-avid disease in patients with mCRPC who progress after conventional therapies identifies a group with poor prognosis and short survival.The |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect